Showing results (181-190 of 324) with videos related to
Sort By:
Pageof 33
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, et al.JTO Clinical and Research Reports|October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLCYi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I TrialKenneth S Thress, Vivien Jacobs, Helen K Angell, et al.The Oncologist|August 5, 2015
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in AsiaHung-Yang Kuo, Zhong-Zhe Lin, Raymond Kuo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2019
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief ReportJames Chih-Hsin Yang, Frances A Shepherd, Dong-Wan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker AnalysisJames Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patientsGee-Chen Chang, Chun-Ming Tsai, Kun-Chieh Chen, et al.International Journal of Cancer|November 29, 2018
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutationsYen-Ting Lin, Jin-Shing Chen, Wei-Yu Liao, et al.Oncology Reports|November 7, 2012
Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cellsYa-Chun Lee, Liang-Ming Lee, Chih-Hsin Yang, et al.Pageof 33